Sign In
Buy AMLX
$13.20
-0.0900 (-0.677%)
At Close: Jun 03, 2026
Amylyx to stop development of rare brain disorder drug after trial failure
07:28am, Wednesday, 27'th Aug 2025
Amylyx Pharmaceuticals said on Wednesday it will discontinue development of its experimental drug for a rare brain disorder after the treatment failed to show benefit in a mid-stage trial.
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
09:00am, Tuesday, 26'th Aug 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences.
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript
10:35pm, Thursday, 07'th Aug 2025
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Camille L. Bedrosian - Chief Medical Officer James M.
Amylyx (AMLX) Q2 Net Loss Narrows 43%
11:13am, Thursday, 07'th Aug 2025
Amylyx (AMLX) Q2 Net Loss Narrows 43%
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results
07:00am, Thursday, 07'th Aug 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results.
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
09:00am, Thursday, 31'st Jul 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025.
Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential
04:26pm, Monday, 21'st Jul 2025
Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Amylyx (AMLX) To Contact Him Directly To Discuss Their Options
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery
02:15pm, Monday, 14'th Jul 2025
Amylyx Pharmaceuticals, Inc. AMLX on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocr
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of new exploratory analyses from the Phase 2 PREVENT
Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025
07:00am, Tuesday, 08'th Jul 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025.
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. (NA
Why Shares in Amylyx Pharmaceuticals Soared This Week
07:56am, Friday, 27'th Jun 2025
Shares in Amylyx Pharmaceuticals (AMLX 3.83%) were up almost 28% in the week to Friday morning. The move comes after an analyst at Guggenheim initiated coverage of the small-cap stock and issued a buy
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market
02:59pm, Tuesday, 24'th Jun 2025
Guggenheim Partners on Monday initiated coverage on Amylyx Pharmaceuticals, Inc. AMLX, noting the company is poised to open post-bariatric hypoglycemia's (PBH) blockbuster potential.
NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Com
